Modulation of MK-801-induced behaviour by noradrenergic agents in mice

Psychopharmacology

Volumn 154, Issue 2, 2001, Pages 177-188

  Harkin, Andrew ^a   Morris, Kathleen ^a   Kelly, John P ^a   O'Donnell, James M ^a   Leonard, Brian E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Activity; Mice; MK 801; Noradrenaline; Reboxetine; Stereotypy

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DESIPRAMINE; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PRAZOSIN; REBOXETINE; YOHIMBINE;

ALPHA ADRENERGIC STIMULATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; ATAXIA; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; NORADRENALIN BRAIN LEVEL; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; RECEPTOR BLOCKING; SEROTONINERGIC SYSTEM; STEREOTYPY;

ADRENERGIC AGENTS; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ATAXIA; BENZYLAMINES; CLONIDINE; DESIPRAMINE; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; FRONTAL LOBE; MALE; MESENCEPHALON; MICE; MORPHOLINES; MOTOR ACTIVITY; NOREPINEPHRINE; PRAZOSIN; STEREOTYPED BEHAVIOR;

EID: 0035118693     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000630     Document Type: Article

References (63)

1. Phencyclidine-induced psychosis
2. Neurotransmitter interactions in schizophrenia - Therapeutic implications
3. 2A receptor antagonist MDL 100, 907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse-implications for psychosis
4. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinsons disease
5. 2A receptor antagonist M 100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice
6. Central sympathomimetic activity of (+)-5-methyl-10, 11 dihydro 5H-dibenzo-[a, d] cyclohepten-5, 10imine (MK-801), a substance with potent anticonvulsant central sympathomimetic and apparent anxiolytic properties
7. Forced swim test-induced endocrine and immune changes in the rat: Effect of subacute desipramine treatment
8. Re-boxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat
9. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviours
10. Evidence for involvement of brain dopamine and other mechanisms in the behavioural action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats
11. Effect of desipramine and amphetamine on noradrenergic neurotransmission: Electro-physiological studies in rat brain
12. A glutamatergic hypothesis of schizophrenia: Rationale for pharmacotherapy with glycine
13. Behavioural, biochemical and histological effects of trimethyltin (TMT) induced brain damage in the rat brain
14. The novel anticonvulsant MK-801 binds to an activated state of the N-methyl-D-aspartate receptor in rat brain
15. The role of norepinephrine in the pathophysiology of cognitive disorders: Potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimers' disease
16. Restoration of ascending noradrenergic projections by residual locus coeruleus neurons: Compensatory response to neurotoxin-induced cell death in the adult rat brain
17. Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area
18. Acute action of DSP-4 on central norepinephrine axons: Biochemical and immunohistochemical evidence for differential effects
19. Pharmacological modifications of the neurotoxic action of the noradrenaline neurotoxin DSP-4 on central noradrenaline neurons
20. Behavioural interactions of antidepressants with the non-competitive NMDA receptor antagonists MK-801 and phencyclidine
21. Test conditions influence the response to drug challenge in rodents
22. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression
23. Quantification of presynaptic alpha-2 adrenoceptors in rat brain after short-term DSP-4 lesioning
24. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats
25. Brain noradrenaline and schizophrenia
26. Recent advances in the phencyclidine model of schizophrenia
27. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
28. Brain noradrenergic receptor in major depression and schizophrenia
29. Effects of antidepressants on the glutamatergic system in mouse brain
30. Schizophrenia: Elevated cerebrospinal fluid norepinephrine
31. Differential effects of DSP-4 administration an regional bran norepinephrine turnover in rats
32. The behavioural effects of MK-801 in rats: Involvement of dopaminergic, serotonergic and noradrenergic systems
33. Effects of the novel 5-HT1A receptor antagonist, (+)-WAY 100135, on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats
34. Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats
35. The effects of anti-depressant drugs on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist
36. MK-801-induced hyperlocomotion: Differential effects of M 100907, SDZ PSD 958 and raclopride
37. Noradrenaline in the brain: Progress in theories of behavioural function
38. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens
39. Atypical antipsychotic drugs
40. Mice with reduced NMDA receptor expression display behaviours related to schizophrenia
41. 5-HT2A receptor antagonists block MK-801-induced stereotypy and hyperlocomotion
42. Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine
43. Altered thermoregulatory response to clonidine in streptozocin-diabetic rats
44. NMDA receptor hypofunction model of schizophrenia
45. Down-regulation of cortical beta-adrenceptors by chronic treatment with functional NMDA antagonists
46. The effects of MK-801 on body temperature and behavior in the rat: Cross-sensitization and cross-tolerance with phencyclidine
47. Rotational behaviour produced by unilateral ventral noradrenergic bundle lesions: Evidence for a noradrenergic-dopaminergic interaction in the brain
48. Effects of acute and chronic antidepressant administration on phencycli-dine (PCP) induced locomotor hyperactivity
49. Tricyclic antidepressants block N-methyl-D-aspartate receptors: Similarities to the action of zinc
50. Effect of reboxetine, a new antidepressant drug on the central noradrenergic system: Behavioral and biochemical studies
51. Neurochemistry of midbrain doapmine neurons
52. An automated direct injection HPLC method for the elctrochemical/fluorimetric quantitation of monoamines and related compounds optimized for screening of large numbers of animals
53. The behavioural and neurochemical effects of phencyclidine in humans and animals - Some implications for modelling psychosis
54. Behavioral rating scales assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats
55. Electrophysiology of brain noxadrenaline neurons and the mode of action of antide-pressant drugs
56. Schizophrenia and glutamatergic transmission
57. Effects of DSP-4 on monoamine and monoamine metabolite levels and on beta adrenoceptor binding kinetics in rat brain at different times after administration
58. The involvement of subtypes of the 5-HT1 receptor and of catecholamine systems in the behavioural response to 8-hydroxy-2-(di-n-propylami-no) tetralin in the rat
59. Antide-pressant actions on brain noradrenergic neurons
60. Modulation of MK-801 response by dopamine agents in mice
61. Neuropathological studies of schizophrenia. An integrated perspective
62. Atypical antipsy-chotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128, 907
63. Reboxetine: A pharmacologically potent, selective and specific norepinephrine reuptake inhibitor